Wellington Management Group LLP Purchases 60,087 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Wellington Management Group LLP boosted its position in shares of Humacyte, Inc. (NASDAQ:HUMA) by 30.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 254,411 shares of the company’s stock after acquiring an additional 60,087 shares during the period. Wellington Management Group LLP’s holdings in Humacyte were worth $1,384,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in shares of Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares in the last quarter. Thrivent Financial for Lutherans acquired a new position in Humacyte during the 3rd quarter valued at about $712,000. Millennium Management LLC increased its position in Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after buying an additional 1,334,641 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Humacyte by 62.7% in the second quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock valued at $1,219,000 after buying an additional 97,931 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Humacyte by 1,018.4% in the second quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock worth $1,230,000 after acquiring an additional 233,422 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the transaction, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,500,000 shares of company stock worth $6,606,799. Insiders own 11.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HUMA shares. Benchmark restated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Thursday, November 21st. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Finally, EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $13.00.

Humacyte Trading Down 2.3 %

Shares of Humacyte stock opened at $3.46 on Friday. Humacyte, Inc. has a 1 year low of $2.48 and a 1 year high of $9.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The stock has a market cap of $435.47 million, a PE ratio of -2.58 and a beta of 1.38. The firm has a fifty day moving average price of $4.85 and a 200 day moving average price of $5.87.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.